PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.34 - 0.34
0.23 - 0.41
110.0K / 51.2K (Avg.)
-1.33 | -0.26
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-68.47%
Negative revenue growth while 8198.HK stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-65.37%
Negative gross profit growth while 8198.HK is at 1.01%. Joel Greenblatt would examine cost competitiveness or demand decline.
No Data
No Data available this quarter, please select a different quarter.
6.14%
Operating income growth under 50% of 8198.HK's 68.75%. Michael Burry would be concerned about deeper cost or sales issues.
10.76%
Net income growth under 50% of 8198.HK's 67.17%. Michael Burry would suspect the firm is falling well behind a key competitor.
7.69%
EPS growth under 50% of 8198.HK's 67.43%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
7.69%
Diluted EPS growth under 50% of 8198.HK's 67.43%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-0.00%
Share reduction while 8198.HK is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
49.88%
OCF growth of 49.88% while 8198.HK is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
49.71%
FCF growth of 49.71% while 8198.HK is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
-97.45%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-96.44%
Negative 5Y CAGR while 8198.HK stands at 13.26%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-90.02%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
115.36%
Positive long-term OCF/share growth while 8198.HK is negative. John Neff would see a structural advantage in sustained cash generation.
-73.17%
Negative 5Y OCF/share CAGR while 8198.HK is at 53.40%. Joel Greenblatt would question the firm’s operational model or cost structure.
185.35%
3Y OCF/share CAGR above 1.5x 8198.HK's 81.29%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-313.99%
Negative 10Y net income/share CAGR while 8198.HK is at 6.66%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-501.36%
Negative 5Y net income/share CAGR while 8198.HK is 76.84%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-1283.84%
Negative 3Y CAGR while 8198.HK is 85.50%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-28.65%
Negative equity/share CAGR over 10 years while 8198.HK stands at 113.77%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-32.91%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-33.75%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
-100.00%
Cut dividends over 10 years while 8198.HK stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-70.56%
Firm’s AR is declining while 8198.HK shows 0.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-53.13%
Inventory is declining while 8198.HK stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-11.37%
Negative asset growth while 8198.HK invests at 0.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-9.24%
We have a declining book value while 8198.HK shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-20.58%
We’re deleveraging while 8198.HK stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-67.07%
Our R&D shrinks while 8198.HK invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-20.36%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.